Features HIV Industry Report: Major Developments in Treatment of HIV/AIDS

Published: Tue Apr 12 2005

POINT ROBERTS, Wash.; April 12, 2005,, an investor and industry news portal for the Aids sector within the content portfolio is pleased to feature the Griffin Biotechnology/ Pharmaceuticals HIV/AIDS Industry Report, April 2005.

The report features various approaches to attacking HIV currently in development including’s featured company, Aethlon Medical's (OTCBB: AEMD) Hemopurifier(tm) which, according to the report, "may offer exciting adjunct solutions to traditional anti-viral therapy".

Public Companies mentioned in the report include: Abbott Pharmaceuticals, Aethlon Medical (OTCBB: AEMD, Sanofi Pasteur (NYSE: SNY), Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co, Pfizer, Roche Pharmaceuticals and VaxGen Inc.

Griffin, HIV/AIDS Industry Report, April 2005

Analysts: Chrystyna Bedrij, Thomas Finnigan, Scott C. Matchett, CFA

Link to Full Report:

The website does not make recommendations, but offers a unique free information portal regarding AIDS Research, Biotech Companies in AIDS Research news, HIV diagnostics, therapeutics, treatments, Infectious Disease Research, news, articles and participating public companies.

Additional Biotech Stocks Info:

Featured Company: Aethlon Medical (OTCBB: AEMD)
Aethlon is pioneering the development of viral filtration devices that rapidly reduce the presence of infectious disease and toxins in the body. Aethlon has published compelling human blood studies of the Hemopurifier(TM) to treat HIV/AIDS and Hepatitis-C (HCV), and most recently, has announced that it is developing pathogen filtration devices to treat infectious agents used in biological warfare and terrorism. The Hemopurifier is a proprietary platform technology that converges the established scientific principles of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur.

Aethlon Medical, Inc. recently announced that it has been advised by Qualtran LLC, a contract research organization (CRO) managing clinical trials for Aethlon in India, that both the Government of India and Industry are supportive of Aethlon's upcoming HIV and Hepatitis-C trials.

Aethlon Medical (OTCBB: AEMD) is presenting in the upcoming online Audio Conference April 6th, 2005

Forum/Conference link:

About Griffin: Griffin Group plc is listed on the London Stock Exchange, Alternative Investment Market, under the symbol: "GFF" and as an ADR sponsored by The Bank of New York under the symbol "GGPFY".

Griffin's New York offices: Griffin Securities, Inc
17 State Street, NY, NY 10004

Investor Incite Newsletter's free "Investor Incite" Newsletter consists of company and industry updates, investment research and developing trends in key areas such as Homeland Security, Renewable Energy, Nanotechnology and more.

TO SIGN UP, click here:

Read the exclusive Feature "The Insiders Corner", a weekly feature by well-known financial writer and author Michael Brush.

Disclaimer: ECON Investor Relations Inc is the owner of the domain Our site does not make recommendations, but offers a unique information portal to investors to research news, articles, and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell any specific products or securities. All investments involve risk. Although we attempt to research thoroughly, we offer no guarantees as to the accuracy of any information presented. We encourage all investors to use our sites only as a resource to further their own research. The site is currently compensated for by its "featured companies, Aethlon Medical: Three thousand dollars per month, plus restricted shares equivalent to five thousand dollars per month.

Dawn Van Zant / Trevor Ruehs
Toll free: 800-665-0411
Email: or
Contact Name: Dawn Van Zant
Contact Email:
Contact Phone: 800-665-0411

Visit website »